Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia

References

• Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–3205.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949–2962.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–565.
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group. J clin oncol. 2013;31(5):599–607.
   PubMed Web of Science ®Google Scholar
• Gorman MF, Ji L, Ko RH, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a therapeutic advances in childhood leukemia (TACL) consortium study. Pediatr Blood Cancer. 2010;55:421–429.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Bourquin J-P, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011;118(20):5409–5415.
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Chang M, Steuber CP, et al. pediatric oncology group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005;19(12):2101–2116.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543–552.
   PubMed Web of Science ®Google Scholar
• Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021–3032.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A phase 3 randomized trial for patients with De Novo AML comparing standard therapy including gemtuzumab ozogamicin (GO) to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT04293562
   Google Scholar
• ClinicalTrials.gov. Safety and effectiveness of quizartinib in children and young adults with acute myeloid leukemia (AML), a cancer of the blood. Available from: https://clinicaltrials.gov/ct2/show/NCT03793478
   Google Scholar
• Momparler RL, Karon M, Siegel SE, et al. Effect of Adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36(8):2891–2895.
   PubMed Web of Science ®Google Scholar
• Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130–2138.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863.
   PubMed Web of Science ®Google Scholar
• Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214–1223.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246.
   PubMed Web of Science ®Google Scholar
• Lin TL, Rizzieri DA, Ryan DH, et al. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021;5(6):1719–1728.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II,multicenter,randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121(2):234–242.
   PubMed Web of Science ®Google Scholar
• Carol H, Fan MMY, Harasym TO, et al. Efficacy of CPX-351,(cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the pediatric preclinical testing program. Pediatr Blood Cancer. 2015;62(1):65–71.
   PubMed Web of Science ®Google Scholar
• Cooper TM, Absalon MJ, Alonzo TA, et al. Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the children’s oncology group. J clin oncol. 2020;38(19):2170–2177.
   PubMed Web of Science ®Google Scholar
• Kasahara K, Fujiwara Y, Sugimoto Y, et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. JNCI. 1992;84(2):113–118.
   PubMedGoogle Scholar
• Domer PH, Head DR, Renganathan N, et al. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia. 1995;9(8):1305–1312.
   PubMed Web of Science ®Google Scholar
• Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council’s 10th AML trial (MRC AML10). Adult and childhood leukaemia working parties of the medical research council. Blood. 1997;89:2311–2318.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360–3368.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015;16(1):95–106.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Trabal A, Gibson A, McCall D, et al. Venetoclax for acute myeloid leukemia in pediatric patients: a texas medical center collaboration. Blood. 2021;138:1247.
   Google Scholar
• Pommert L, Schafer ES, Malvar J, et al. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022;97:613–622.
   PubMed Web of Science ®Google Scholar
• Winters AC, Maloney KW, Treece AL, et al. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer. 2020;67(10):e28398.
   PubMed Web of Science ®Google Scholar
• Gore L, Triche TJ, Farrar JE, et al. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017;9(1):108.
   PubMedGoogle Scholar
• ClinicalTrials.gov. Azacitidine, venetoclax, and gilteritinib in treating patients with Recurrent/Refractory FLT3-mutated acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic Syndrome/Myeloproliferative neoplasm. Available from: https://clinicaltrials.gov/ct2/show/NCT04140487
   Google Scholar
• Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654–3661.
   PubMed Web of Science ®Google Scholar
• Tarlock K, Alonzo TA, Gerbing RB, et al. Distinct co-occurring mutational profiles in acute myeloid leukemia confers prognostic significance in children and young adults with FLT3/ITD mutations. Blood. 2018;132(Supplement 1):443.
   Google Scholar
• Levis MJ, Perl AE, Martinelli G, et al. Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3 mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3 -ITD allelic ratio. J clin oncol. 2019;37(15_suppl):7000.
   Web of Science ®Google Scholar
• Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29(24):3293–3300.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a children’s oncology group phase I consortium report. Clin Cancer Res off J Am Assoc Cancer Res. 2012;18(21):6011–6022.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Gerbing R, et al. sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the children’s oncology group protocol AAML1031. J clin oncol. 2022;40(18):2023–2035. Jco2101612.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of the safety and preliminary efficacy of oral midostaurin (PKC412) in relapsed or refractory pediatric leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00866281
   Google Scholar
• ClinicalTrials.gov. A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy and pharmacokinetics in newly diagnosed pediatric patients with FLT3 mutated AML; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03591510
   Google Scholar
• Kampa-Schittenhelm KM, Heinrich MC, Akmut F, et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer. 2013;12(1):19.
   PubMedGoogle Scholar
• Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903.
   PubMed Web of Science ®Google Scholar
• Cooper TM, Cassar J, Eckroth E, et al. A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) study. Clin Cancer Res. 2016;22(16):4014–4022.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kolb EA, Mires DE, et al. A phase 1/2 study of quizartinib (Q) in combination with re-induction chemotherapy and as single-agent continuation therapy in pediatric and young adult patients with Relapsed/Refractory (R/R) FLT3-ITD acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):3937.
   Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061–1075.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139(23):3366–3375.
   PubMed Web of Science ®Google Scholar
• McCall D, Roth M, Mahadeo KM, et al. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021;5(23):5215–5219.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of gilteritinib (ASP2215) combined with chemotherapy in children, adolescents and young adults with FMS-like tyrosine kinase 3 (FLT3)/Internal tandem duplication (ITD) positive relapsed or refractory acute myeloid leukemia (AML). Available from: https://clinicaltrials.gov/ct2/show/NCT04240002
   Google Scholar
• ClinicalTrials.gov. A study to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed AML with or without FLT3 mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT04293562
   Google Scholar
• Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560–566.
   PubMed Web of Science ®Google Scholar
• Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther. 2001;1(5):893–901.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA. A new Dawn for gemtuzumab ozogamicin? Lancet Oncol. 2014;15(9):913–914.
   PubMed Web of Science ®Google Scholar
• Tarlock K, Alonzo TA, Gerbing RB, et al. gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the children’s oncology group. Clin Cancer Res. 2016;22(8):1951–1957.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Guest E, Alonzo TA, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children’s oncology group trial AAML0531. J clin oncol. 2021;39(28):3149–3160.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Loken M, Gerbing RB, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III children’s oncology group trial AAML0531. J clin oncol. 2016;34(7):747–755.
   PubMed Web of Science ®Google Scholar
• Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood. 2012;120(5):978–984.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21(4):551–560.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study evaluating the safety, tolerability, pharmacokinetics and preliminary activity of idasanutlin in combination with either chemotherapy or venetoclax in treatment of pediatric and young adult participants with Relapsed/Refractory acute leukemias or solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT04029688
   Google Scholar
• Place AE, Goldsmith K, Bourquin JP, et al. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future Oncol. 2018;14(21):2115–2129.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Venetoclax combined with vyxeos (CPX-351) for participants with relapsed or refractory acute leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT03826992
   Google Scholar
• ClinicalTrials.gov. Study of Selinexor and venetoclax in combination with chemotherapy in pediatric and young adult patients with refractory or relapsed acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT04898894
   Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–3331.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Brivio E, Baruchel A, Beishuizen A, et al. Targeted inhibitors and antibody immunotherapies: novel therapies for paediatric leukaemia and lymphoma. Eur J Cancer. 2022;164:1–17.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Pievani A, Biondi A, et al. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13–22.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Kramer M, Rollig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218.
   PubMed Web of Science ®Google Scholar
• Tambaro FP, Singh H, Jones E, et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021;35(11):3282–3286.
   PubMed Web of Science ®Google Scholar
• Sallman D, Elmariah H, Sweet K, et al. Phase 1/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. ASH Annu Meeting. 2021.
   Google Scholar
• Liu F, Cao Y, Pinz K, et al. First-in-Human CLL1-CD33 Compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132(Supplement 1):901.
   Google Scholar
• ClinicalTrials.gov. Study of anti-CD33 chimeric antigen receptor-expressing T cells (CD33CART) in children and young adults with Relapsed/Refractory acute myeloid leukemia. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03971799?term=CAR&recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=3
   Google Scholar
• ClinicalTrials.gov. PLAT-08: a study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML. Available from: https://clinicaltrials.gov/ct2/show/NCT05105152?recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=1
   Google Scholar
• ClinicalTrials.gov. Chimeric antigen receptor T-cells for the treatment of AML expressing CLL-1 antigen. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04219163?term=CAR&recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=1
   Google Scholar
• Konopleva M, Rissling I, Andreeff M. CD38 in hematopoietic malignancies. Chem Immunol. 2000;75:189–206.
   PubMedGoogle Scholar
• Jelinek T, Zabaleta A, Perez C, et al. Pre-clinical efficacy of the Anti-CD38 monoclonal antibody (mAb) isatuximab in acute myeloid leukemia (AML). Blood. 2017;130:2655.
   Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321.
   PubMed Web of Science ®Google Scholar
• Baruchel A, Abrahamsson J, Bertrand Y, et al. Isatuximab in combination with chemotherapy in pediatric patients with Relapsed/Refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim Analysis. Blood. 2021;138(Supplement 1):516.
   Google Scholar
• Cui Q, Qian C, Xu N, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):82.
   PubMed Web of Science ®Google Scholar
• Bras AE, de Haas V, van Stigt A, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry B Clin Cytom. 2019;96(2):134–142.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. CD123 redirected T cells for AML in pediatric subjects. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04678336?term=CAR&recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=4
   Google Scholar
• ClinicalTrials.gov. CD123-directed autologous T-cell therapy for acute myelogenous leukemia (CATCHAML). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04318678?term=CAR&recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=2
   Google Scholar
• Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343–2354.
   PubMed Web of Science ®Google Scholar
• Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer. 2020;8(1): e000845.
   PubMed Web of Science ®Google Scholar
• Economides MP, McCue D, Lane AA, et al. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019;12(10):941–946.
   PubMed Web of Science ®Google Scholar
• Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751–762.
   PubMed Web of Science ®Google Scholar
• Daver NG, Montesinos P, DeAngelo DJ, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with Relapsed/Refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2019;134(Supplement_1):734.
   Web of Science ®Google Scholar
• Penticuff JC, Woolbright BL, Sielecki TM, et al. MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nat Rev Urol. 2019;16(5):318–328.
   PubMed Web of Science ®Google Scholar
• Schröder B. The multifaceted roles of the invariant chain CD74–More than just a chaperone. Biochim Biophys Acta. 2016;1863(6):1269–1281.
   PubMed Web of Science ®Google Scholar
• Ruvolo PP, Hu CW, Qiu Y, et al. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine. 2019;44:126–137.
   PubMed Web of Science ®Google Scholar
• Su H, Na N, Zhang X, et al. The biological function and significance of CD74 in immune diseases. Inflamm Res. 2017;66(3):209–216.
   PubMed Web of Science ®Google Scholar
• Brodersen L, Hudson C, Alonzo T, et al. Newly diagnosed childhood AML patients treated with bortezomib show superior survival If CD74 is expressed: a report of 991 patients from the children’s oncology group AAML1031 protocol. Blood. 2020;136.
   Web of Science ®Google Scholar
• Shah NN, Mattour AH, Popplewell LL, et al. Preliminary results of an ongoing phase 1 dose escalation study of the novel anti-CD74 antibody drug conjugate (ADC), STRO-001. patients with B-cell non-hodgkin lymphoma. Blood. 2020;136:29–30.
   Web of Science ®Google Scholar
• Nguyen R, Wu H, Pounds S, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7(1):81.
   PubMedGoogle Scholar
• Bednarski JJ, Zimmerman C, Berrien-Elliott MM, et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022;139(11):1670–1683.
   PubMedGoogle Scholar
• ClinicalTrials.gov. FT538 in combination with daratumumab in AML acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT04714372?recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=10
   Google Scholar
• ClinicalTrials.gov. A phase 1 trial of CIML NK cell infusion for myeloid disease relapse after hematopoietic cell transplantation. Available from: https://clinicaltrials.gov/ct2/show/NCT04024761?recrs=a&cond=Aml&cntry=US&age=0&draw=2
   Google Scholar
• ClinicalTrials.gov. Cytokine induced memory-like NK cell adoptive therapy for relapsed AML after allogeneic hematopoietic cell transplant. Available from: https://clinicaltrials.gov/ct2/show/NCT03068819?recrs=a&cond=Aml&cntry=US&age=0&draw=2&rank=9
   Google Scholar
• Turk S, Turk C, Akbar MW, et al. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS One. 2020;15(11):e0242497.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Martin LP, Oaknin A, et al. STRO-002-GM2: a phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers). J clin oncol. 2022;40: TPS5622.
   Web of Science ®Google Scholar
• Masetti R, Bertuccio SN, Pession A, et al. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol. 2019;184(3):337–347.
   PubMed Web of Science ®Google Scholar